Highlights•Microbiome alterations are associated with infection, GVHD, and other adverse
transplant outcomes.•“Multiomic” technologies may better identify clinically actionable …

Hematopoietic stem-cell transplantation is associated with a profound immune deficiency
manifested as an increased propensity to develop infections and probably also …

Autologous stem cell transplantation (ASCT) improves survival in patients with previously
untreated multiple myeloma (MM) and relapsed, chemotherapy-sensitive, aggressive non …

Purpose: Patients with metastatic or relapsed pediatric sarcomas receive cytotoxic regimens
that induce high remission rates associated with profound lymphocyte depletion, but …

Day 15 absolute lymphocyte count (ALC-15) after autologous peripheral blood
hematopoietic stem cell transplantation (APHSCT) has been reported to be a significant …

High-dose chemotherapy in conjunction with auto-SCT is the preferred treatment of relapsed
Hodgkin disease and non-Hodgkin lymphoma and newly diagnosed multiple myeloma …

Although stem cell mobilization has been performed for more than 20 years, little is known
about the effects of mobilizing agents on apheresis composition and the impact of graft cell …

Autologous stem cell transplantation (ASCT) is the standard of care for patients with multiple
myeloma younger than 70 years. However, despite this aggressive therapy most patients …

Multiple therapeutic options exist for multiple myeloma (MM), including autologous
hematopoietic stem cell transplantation (AHSCT). Measurement of minimal residual disease …

Absolute lymphocyte count at day 15 (ALC-15) after autologous peripheral blood
hematopoietic stem cell transplantation (APHSCT) is an independent prognostic factor for …